Inhaled antibiotics: an answer to MDR pathogens?

Jordi Rello (Barcelona, Spain)

Source: International Congress 2015 – PG14 Antibiotic stewardship for respiratory infections

Session: PG14 Antibiotic stewardship for respiratory infections
Session type: Postgraduate Course
Number: 170

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Jordi Rello (Barcelona, Spain). Inhaled antibiotics: an answer to MDR pathogens?. International Congress 2015 – PG14 Antibiotic stewardship for respiratory infections

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009
Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010
Inhaled antibiotics, pneumonia and bacterial resistance in the ICU Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018
Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013
Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017
Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough? Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012
Inhaled antibiotics: strengths and fears Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016
Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013
Therapeutic strategies in pneumonia: going beyond antibiotics Source: Eur Respir Rev 2015; 24: 516-524 Year: 2015
Antibiotic resistance in pulmonary infections: mechanisms and epidemiology Source: Eur Respir Monogr 2017; 75: 21-43 Year: 2017
Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019
Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012